April 7 (Reuters) - Lexeo Therapeutics Inc LXEO.O:
LEXEO THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1/2 DATA FOR LX2006 IN FRIEDREICH ATAXIA CARDIOMYOPATHY SUPPORTING ADVANCEMENT TO REGISTRATIONAL STUDY
LEXEO THERAPEUTICS INC: LX2006 GENERALLY WELL TOLERATED WITH NO SIGNS OF COMPLEMENT ACTIVATION OR OTHER IMMUNOGENICITY TO DATE
LEXEO THERAPEUTICS : PARTICIPANTS WITH ABNORMAL LEFT VENTRICULAR MASS INDEX AT BASELINE ACHIEVED 25% MEAN REDUCTION IN LVMI BY 12 MONTHS OR SOONER
LEXEO THERAPEUTICS : CLINICALLY MEANINGFUL IMPROVEMENTS IN MAJORITY OF PARTICIPANTS ACROSS CARDIAC BIOMARKERS & FUNCTIONAL MEASURES
Source text: ID:nGNX4F00MX
Further company coverage: LXEO.O
(((( Reuters.briefs@thomsonreuters.com ;));))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。